The Egyptian Drug Authority (EDA) held the inaugural meeting of the Permanent Committee for the Drafting of the Egyptian Pharmacopoeia. The Committee was established pursuant to Decision No. 154 of 2020 issued by Professor Dr. Tamer Essam, Chairman of the Egyptian Drug Authority.
Dr. Ayman El-Khatib, Vice President of the Egyptian Drug Authority and Chairman of the Permanent Committee for the Drafting of the Egyptian Pharmacopoeia, stated that the Committee had been entrusted with the responsibility of issuing the Egyptian Pharmacopoeia and its supplementary volumes, pharmaceutical compendia, and subsequent editions whenever required. The Committee is also mandated to conduct studies related to the revision and updating of the Pharmacopoeia, supervise its publication and dissemination, and maintain communication with counterpart organizations in other countries in order to exchange expertise and remain abreast of emerging developments in the fields of medicines and biological products.
Dr. El-Khatib further noted that the Committee was undertaking a comprehensive review of the structures and frameworks adopted by leading international pharmacopoeias. In parallel, efforts were underway to establish specialized technical committees and to digitize the Committee's operations. These measures are intended to capitalize on scientific expertise and internationally recognized references and to ensure that the Egyptian Pharmacopoeia is developed in accordance with the latest scientific and technological advances.
The objective of these efforts is to establish clear and authoritative scientific and regulatory standards governing all aspects of the pharmaceutical sector, thereby contributing directly to improving the quality of medicinal products available in the Egyptian market, ensuring the safety and efficacy of medicines reaching patients, and enhancing the reputation and competitiveness of Egyptian pharmaceutical products in regional and international markets.
Dr. El-Khatib added that the coming period would witness the organization of additional meetings aimed at initiating the drafting process of the new Egyptian Pharmacopoeia at the earliest opportunity. He emphasized that the Committee maintains an open and collaborative approach toward all international and national reference bodies, research centers, and academic institutions in order to develop a scientifically robust and procedurally sound final framework.